One Six 8 Ventures
Operator-led venture capital firm investing in early-stage medical technology companies.
Website: https://www.onesix8ventures.com/
Cover Block
Publicly reported
| Field | Detail |
|---|---|
| Name | One Six 8 Ventures |
| Tagline | Operator-led venture capital firm investing in early-stage medical technology companies. |
| Headquarters | Calgary, Canada [Crunchbase] |
| Founded | 2023 [Crunchbase] |
| Industry | Healthtech |
| Technology | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Funding Label | Undisclosed |
Links
Publicly reported
- Website: https://www.onesix8ventures.com/
- LinkedIn: https://www.linkedin.com/posts/onesix8_medtech-venturecapital-healthinnovation-activity-7425937086031212545-hJXp
Summary and Signal
PUBLIC One Six 8 Ventures is a Calgary-based venture capital firm focused on early-stage medical technology, and it merits investor attention now because public signals suggest it is beginning to convert a clear sector thesis into visible syndicate participation in medtech financings [Crunchbase] [GlobeNewswire, February 2026]. Founded in 2023, the firm presents itself as an operator-led fund built around a gap it sees in backing medtech companies, particularly in under-ventured regions and at the transition from Seed to Series A [Crunchbase] [Digital Journal]. Its core offering is not a software product but a capital-plus-support model: One Six 8 says it invests in AI-enabled medtech, surgical tools and robotics, and remote patient monitoring, while pairing capital with commercialization, strategic, and operating support that is more hands-on than a passive fund model [One Six 8 Ventures] [Digital Journal].
The most relevant public team signal is Judyanna Yu Simcock, identified as a Founding or Managing Partner, whose background includes nearly two decades in finance leadership roles across VC-backed medtech and biotech companies, with additional team members including Venture Partner Min Lang, Anita Nador, Wade Oosterman, and Dr. Charles Stacey cited in public profiles and event materials [LinkedIn, March 2024] [LinkedIn] [LinkedIn, April 2024]. Funding visibility is still limited: no public source in the materials reviewed discloses One Six 8 Ventures' fund size or close, although third-party directory data points to an indicative check range of $500,000 to $1 million and a $750,000 sweet spot (estimated by the directory, not confirmed by the firm) [NFX] [Crunchbase]. On portfolio activity, Tracxn reports one investment in the last 12 months as of February 2026, and GlobeNewswire independently confirms the firm joined Respiree's Series A syndicate in February 2026, which is the clearest current evidence of live deployment pace [Tracxn, February 2026] [GlobeNewswire, February 2026].
Over the next 12 to 18 months, the main items to watch are whether One Six 8 can show a broader pattern of announced deals, whether it discloses more about fund scale and portfolio construction, and whether its operator-support positioning translates into repeat participation in competitive medtech rounds rather than one-off visibility [PitchBook] [GlobeNewswire, February 2026] [One Six 8 Ventures]. The firm has a coherent thesis and relevant domain orientation, but public evidence on cadence, capitalization, and realized differentiation is still early.
One source, partially checked -- Relies on a mix of company materials, LinkedIn profiles, and limited third-party corroboration from GlobeNewswire, Tracxn, Crunchbase, and Digital Journal.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Funding | Undisclosed |
Company Overview
PUBLIC
One Six 8 Ventures presents as a newly formed specialist investor rather than a long-established fund platform. Public company materials describe it as an operator-led venture capital firm focused on early-stage medical technology, and Crunchbase lists the firm as based in Calgary, Canada and founded in 2023 [One Six 8 Ventures] [Crunchbase]. The company site frames the pitch in practical terms: support for early-stage medtech companies, particularly across AI-enabled medtech, surgical tools and robotics, and remote patient monitoring, with an emphasis on commercialization and operating help alongside capital [One Six 8 Ventures].
The chronology that can be verified from company-controlled and directory sources is still fairly short. The firm appears to have been established in 2023, with public-facing materials outlining an ambition to help portfolio companies scale globally from under-ventured regions [Crunchbase] [One Six 8 Ventures]. By 2026, its website highlighted portfolio-related milestones including Fluid Biomed's $27 million Series A financing and ThinkSono's FDA clearance for ThinkSono Guidance, although those are portfolio-company events rather than evidence about One Six 8's own fund size or legal structure [One Six 8 Ventures].
The public record remains thin on corporate particulars that institutional investors often want early. Neither Crunchbase nor the company website, based on the sources reviewed here, discloses a legal entity name beyond the operating brand, founders beyond the publicly visible team pages, or a publicly announced fund size and close date [Crunchbase] [One Six 8 Ventures]. That leaves the clearest current view as a Calgary-based medtech-focused venture firm with a narrow sector brief and a still-developing public footprint [Crunchbase] [One Six 8 Ventures].
One source, partially checked -- Confirmed by Crunchbase and company website, but key corporate details such as legal entity and fund size are not disclosed in the cited public sources.
The Product and the Stack
Public record plus analysis One Six 8 Ventures is not selling a software platform or medical device directly. The product, in practical terms, is an investment and commercialization offering aimed at early-stage medtech founders, with the firm describing its focus as AI-enabled medtech, surgical tools and robotics, and remote patient monitoring [One Six 8 Ventures]. Public materials frame the offering less as passive capital and more as operating support, including strategic and operational guidance, access to a global network, commercialization support, and help with international expansion [One Six 8 Ventures].
That positioning is directionally consistent across third-party mentions, though the detail level remains thin. Digital Journal described the firm as focused on medtech companies moving from Seed to Series A [Digital Journal], while Luma characterized it as backing life-saving technology ventures in under-ventured regions [Luma]. On portfolio evidence, the public record shows exposure to companies in monitoring, neurovascular devices, and diagnostic or imaging workflows, including Respiree, Fluid Biomed, PulseMedica, and ThinkSono, but those examples indicate category preference rather than a proprietary technology stack at the fund level [GlobeNewswire, February 2026] [One Six 8 Ventures].
The main analytical constraint is that most of the capability claims come from company materials rather than independently verified operating evidence. There is enough to say the firm is presenting an operator-led, commercialization-heavy model within medtech, but not enough public evidence to specify repeatable playbooks, internal technical infrastructure, or differentiated tooling beyond the stated advisory and network support [One Six 8 Ventures] [Tracxn, Feb 2026].
No independent source found -- Core capability claims in this section rely primarily on company website materials, with limited third-party corroboration from Digital Journal, Luma, GlobeNewswire, and Tracxn.
The Market They Are Entering
PUBLIC
The market matters now because One Six 8 Ventures is positioned at the intersection of several medtech subcategories, AI-enabled care, surgical robotics, and remote monitoring, where investor interest has stayed ahead of clear public market sizing for this specific firm’s focus set [One Six 8 Ventures] [Digital Journal].
Public evidence is thin on a clean TAM, SAM, and SOM for One Six 8’s stated strategy, so the more defensible approach is to map the firm against adjacent markets rather than manufacture precision. The firm says it targets early-stage companies in AI medtech, surgical tools and robotics, and remote patient monitoring [One Six 8 Ventures]. Digital Journal also describes the firm as focused on medtech companies moving from Seed to Series A, which places it less in a single product market than in an early commercialization financing gap inside healthcare innovation [Digital Journal]. That distinction matters, because the addressable opportunity for an operator-led fund depends not only on end-market demand for devices or monitoring systems, but also on the supply of venture-backable companies that need commercialization support.
The clearest demand drivers in the public record are clinical and commercial rather than purely financial. One Six 8 repeatedly frames its role around helping portfolio companies commercialize and expand internationally, with special attention to under-ventured regions [One Six 8 Ventures]. Luma characterizes the firm as backing life-saving technology ventures in under-ventured regions, which aligns with a broader market logic: medtech founders outside the largest U.S. hubs often face a thinner local capital base, fewer specialized operators, and a more difficult path from technical validation to scaled go-to-market execution [Luma]. The strategy is plausible on its face, but the public materials do not yet quantify how large that founder pipeline is or how often it produces venture-scale outcomes.
Adjacent markets are also relevant because the firm’s stated sectors overlap with several different spending pools. Remote patient monitoring sits close to digital health and care management budgets, while surgical tools and robotics map more directly to capital equipment cycles, hospital procurement, and procedure economics [One Six 8 Ventures]. AI medtech cuts across both, touching clinical workflow software, diagnostics, device intelligence, and monitoring infrastructure [One Six 8 Ventures]. For an investor, that mix can be attractive because it broadens sourcing, but it also means market timing will vary by subcategory. A reimbursement or procurement tailwind that helps one segment may do little for another.
Regulatory and macro conditions appear to be a gating factor rather than a simple tailwind. One Six 8 highlights ThinkSono’s FDA clearance as a milestone linked to U.S. expansion, which is a useful public example of how regulatory progress can unlock commercialization in medtech, even if it says little about the entire portfolio [One Six 8 Ventures]. The same logic cuts the other way. Capital efficiency, time to clearance, hospital budget pressure, and cross-border expansion complexity all shape investability in this category. That likely explains why the firm emphasizes hands-on operating support and why third-party directories place its indicative check size in the $500,000 to $1 million range, with a $750,000 sweet spot, rather than suggesting a broad multi-stage mandate [NFX] [One Six 8 Ventures].
| Market lens | Public sizing claim or signal | Source |
|---|---|---|
| Indicative investment sweet spot | $750,000 | [NFX] |
| Indicative investment range | $500,000 to $1 million | [NFX] |
| Investments in last 12 months, as of Feb. 2026 | 1 | [Tracxn, February 2026] |
The table does not size the end market for medtech itself, but it does anchor the practical market One Six 8 appears to be pursuing: small, selective early-stage positions where domain support is part of the product. The limited disclosed cadence also suggests this is still an emerging platform rather than a scaled deployment engine [Tracxn, February 2026].
No independent source found -- This section relies primarily on company materials for category focus and strategy, with partial third-party corroboration from Digital Journal, Luma, NFX, and Tracxn; no independent public TAM or category sizing specific to the firm’s target segments was confirmed.
The Competitive Field
Competitive positioning
MIXED One Six 8 Ventures sits in a narrower lane than a generalist seed fund: the public record points to an operator-led medtech investor that is trying to win on commercialization help and regional access, not on check size or brand scale alone [One Six 8 Ventures] [Digital Journal] [NFX].
At the incumbent end are larger healthcare venture franchises and institutional medtech specialists that can offer deeper reserves of follow-on capital, broader portfolio signaling, and established syndication patterns, though those firms are not named in the available source set. At the challenger end are newer sector-focused funds and angel networks pursuing early medical-device and AI-enabled care bets, while adjacent substitutes include family offices, strategic corporate investors, and regional innovation programs that can sometimes fill the first institutional round for device companies before a formal venture syndicate is built [Digital Journal] [PitchBook] [Crunchbase].
The public evidence suggests One Six 8's clearest edge today is a combination of operator credibility and a stated willingness to work outside the most crowded venture corridors. Judyanna Yu Simcock is described publicly as a Managing or Founding Partner with nearly two decades of finance and operating experience across VC-backed public and private medtech and biotech companies, and the broader team is presented by the firm as hands-on in commercialization and international expansion [LinkedIn, March 2024] [LinkedIn] [One Six 8 Ventures]. That edge could matter for early medtech founders who need regulatory, capital-planning, and go-to-market guidance at the same time, but it is also perishable if larger funds replicate the service model or if portfolio-support claims remain supported mainly by company materials rather than repeated third-party outcomes [One Six 8 Ventures] [Luma].
The firm appears most exposed where scale economics matter more than specialization. NFX lists an indicative investment range of $500,000 to $1 million, with a $750,000 sweet spot, which is reasonable for first checks but does not by itself confer ownership over follow-on rounds or late-seed pricing power [NFX]. Tracxn says the firm invested in one company in the last 12 months as of February 2026, a data point that may simply reflect a young fund but still leaves less public evidence of pace and portfolio breadth than more established healthcare investors would typically show [Tracxn, Feb 2026]. In practical terms, the strongest substitute is often not another small fund by name, but a better-capitalized syndicate that can underwrite regulatory timelines, clinical evidence generation, and commercial ramp with fewer financing handoffs [GlobeNewswire, February 2026].
The most plausible 18-month scenario is a bifurcation inside early medtech funding. Winner if execution compounds: One Six 8 Ventures, if its operator-led pitch converts into repeated co-investment slots like the Respiree Series A syndicate and more portfolio companies reach visible milestones such as FDA clearance or major financings [GlobeNewswire, February 2026] [One Six 8 Ventures]. Loser if the market shifts back toward scale-first underwriting: smaller specialist entrants without a clearly demonstrated repeatable portfolio cadence, because founders facing longer device timelines may prefer investors that can lead multiple rounds rather than advise through one [Tracxn, Feb 2026] [NFX].
Opportunity
PUBLIC
The size of the prize here is not a conventional venture-firm outcome, but the possibility that One Six 8 Ventures becomes a repeatable gateway between under-ventured medtech startups and global commercialization capital in a category where operator help can matter as much as check size [One Six 8 Ventures] [Digital Journal] [GlobeNewswire, February 2026].
The headline opportunity is to become a specialist medtech investor that founders seek early because the firm offers more than financing. Public materials are consistent on that point, even if most of the evidence is company-originated: One Six 8 positions itself around early-stage medical technology, with emphasis on AI-enabled medtech, surgical tools and robotics, and remote patient monitoring, and says it provides commercialization and operating support rather than capital alone [One Six 8 Ventures]. That becomes more reachable than aspirational because third-party sources at least partially corroborate both the stage focus and the emerging investing activity. Digital Journal describes the firm as focused on companies moving from Seed to Series A [Digital Journal], Tracxn recorded one investment in the last 12 months as of February 2026 [Tracxn, February 2026], and GlobeNewswire named One Six 8 in Respiree's Series A syndicate alongside other healthcare investors [GlobeNewswire, February 2026]. For a young fund founded in 2023, that is a narrow but tangible signal that the firm is entering live syndicates rather than remaining purely narrative [Crunchbase].
The upside paths are still early, but the public record supports a few concrete ways the platform could scale.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Specialist syndicate node | One Six 8 becomes a recurring participant in North American and cross-border medtech financings, especially around Seed to Series A companies that need commercialization help | More financings like Respiree, where the firm is publicly named in a syndicate with established healthcare investors [GlobeNewswire, February 2026] | The firm already markets itself at that stage focus [One Six 8 Ventures], and third-party directory data suggests a check range of $500,000 to $1 million, with a $750,000 sweet spot, which fits syndicated early-stage rounds [NFX] |
| Under-ventured region pipeline owner | The firm builds a differentiated sourcing engine around medtech companies outside the most crowded venture hubs, then uses operating support to move them into broader institutional investor networks | Continued proof that founders from under-vented regions can reach regulatory and commercial milestones after One Six 8 participation [One Six 8 Ventures] [Luma] | The under-ventured-region thesis appears in both company material and third-party profile coverage, which suggests the positioning is central rather than incidental [One Six 8 Ventures] [Luma] |
| Commercialization-first brand | One Six 8 becomes known less as a capital provider and more as an execution partner for medtech founders approaching scale-up, which improves access to selective deals despite a smaller apparent pace of deployment | Publicly visible portfolio milestones such as FDA clearance, later-stage follow-on rounds, or U.S. market expansion among portfolio companies [One Six 8 Ventures] [GlobeNewswire, February 2026] | The firm's public messaging centers on commercialization, strategic guidance, and international expansion support, and the Respiree announcement ties its syndicate expansion to U.S. commercial growth [One Six 8 Ventures] [GlobeNewswire, February 2026] |
The scenarios point in the same direction: if One Six 8 can repeatedly insert itself at the moment a medtech company needs operational help to cross from technical promise into regulated commercialization, it has a chance to earn distribution that is not purely balance-sheet driven.
What compounding looks like here is a reputation flywheel rather than a software network effect. A young specialist fund wins access to one credible Series A syndicate, that deal produces a follow-on milestone, founders and co-investors begin to treat the firm as useful in commercialization work, and the next company is willing to accept One Six 8's capital even if the check is modest. The pieces of that loop are visible in public sources, though only faintly: the firm's website emphasizes strategic and operational guidance and global network access [One Six 8 Ventures], Judyanna Yu Simcock's public profile is framed around nearly two decades as a CFO across VC-backed medtech and biotech businesses [LinkedIn, March 2024], and the team has been publicly associated with portfolio names such as Respiree, ThinkSono, Fluid Biomed, and PulseMedica [GlobeNewswire, February 2026] [One Six 8 Ventures]. If that pattern continues, the moat is not proprietary technology. It is trusted pattern recognition in a hard category where financing, regulation, and go-to-market timing interact.
The size of the win is difficult to anchor precisely because no public source here provides a fund size, management-fee base, ownership levels, or valuation marks for One Six 8 itself [Crunchbase] [PitchBook]. Still, there is a credible way to frame the upside. If the firm becomes a recognized early-stage medtech specialist that consistently enters financings before broader institutional capital, it could matter economically through ownership in later winners and through franchise value with LPs and founders. As one public marker, Respiree's February 2026 announcement shows One Six 8 joining a Series A syndicate built to support U.S. expansion, which is the kind of stage where specialist investors can establish durable positions before category recognition broadens [GlobeNewswire, February 2026]. The public record also cites a $27 million Series A at Fluid Biomed and an FDA-clearance milestone at ThinkSono, both of which suggest the firm is at least trying to align itself with companies that can compound through regulatory and commercial inflection points [One Six 8 Ventures]. The realistic upside case, scenario not a forecast, is a specialist healthcare venture franchise whose value comes from getting into a small number of outsized medtech outcomes early enough for follow-on ownership and brand reinforcement to feed each other.
Thinly sourced -- This section relies on a mix of company materials, one named financing announcement, one third-party directory investment count, and directory-style check-size data that is only partially corroborated [One Six 8 Ventures] [GlobeNewswire, February 2026] [Tracxn, February 2026] [NFX].
Sources
Publicly reported
[Crunchbase] One Six 8 Ventures - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/one-six-8-ventures
[GlobeNewswire, February 2026] Respiree Strengthens Series A Syndicate to Advance Next-Generation Cardiorespiratory Care | https://www.globenewswire.com/news-release/2026/02/24/3243763/0/en/Respiree-Strengthens-Series-A-Syndicate-to-Advance-Next-Generation-Cardiorespiratory-Care.html
[Digital Journal] Can smarter investment help Canadian medtech go global? | https://www.digitaljournal.com/article/can-smarter-investment-help-canadian-medtech-go-global/
[One Six 8 Ventures] One Six 8 Ventures Operator-Led MedTech Venture Capital Fund | https://www.onesix8ventures.com/
[LinkedIn, March 2024] Investing in Life Sciences with Judyanna Yu | https://www.linkedin.com/posts/catherinetgray_investing-in-life-sciences-with-judyanna-activity-7419831320568098817-CSxD
[LinkedIn] Judyanna Yu Simcock's Post | https://www.linkedin.com/posts/judyanna_excited-to-share-that-one-six-8-ventures-activity-7274450985651990530-OzVa
[Tracxn, February 2026] One Six 8 Ventures - 2026 Investor Profile, Team & Investment Trends - Tracxn | https://tracxn.com/d/venture-capital/onesix8ventures/__Nhorijna1IhKsxQRWdwofB7tAFGl3Tl2Zy6VSs_vT9Q
[PitchBook] One Six 8 Ventures investment portfolio | PitchBook | https://pitchbook.com/profiles/investor/718973-83
Articles about One Six 8 Ventures
- One Six 8 Ventures' First Check Is for the MedTech Company Calgary Missed — The new operator-led fund is betting that hands-on commercialization support, not just capital, can scale Canadian health tech.